Leaders of the Republican-controlled Senate today gave up on holding full vote this week on their effort to repeal and replace the Affordable Care Act.
Supporters of the Senate’s Better Care Reconciliation Act (BCRA), as well as similar Obamacare repeal efforts in the House, say their bills are part of the answer to, among other things, stopping the escalating price of medical care.
Whether the GOP proposals will do that is debatable — or not, depending on the eventual floor vote rules set on the Upper Chamber bill and any possible House-Senate health care conference legislation.
But a group of Democratic Senators aren’t waiting for that battle. They have introduced their own bill that would penalize pharmaceutical companies that dramatically raise product prices.
Aiming to end drug price hikes: Led by Sens. Sherrod Brown (D-Ohio), the Stop Price Gouging Act (S. 1369) targets price spikes for patients who rely on medication to treat diseases such as cancer and opioid addiction.
The two major components of S. 1369 would
- Require drug companies to report increases in drug prices and justify the increase, and
- Penalize drug companies that engage in unjustified price increases with financial penalties proportionate to the price spike.
Any money collected as part of this new excise tax would be directed to the National Institutes of Health for research and development of drugs.
Patient price of higher drug costs: In 2015, Americans spent an all-time high of $324 billion on prescription drugs, Brown said in announcing introduction of The Stop Price Gouging Act.
He also cited Consumer Reports, which says nearly 28 million Americans have personally experienced a spike in the cost of their prescription medications over the past year.
“The purpose of prescription drugs is to allow Ohioans to live longer, healthier lives – not to line the pockets of Big Pharma executives,” said Brown. “Too many Ohioans still struggle to afford the medicine they need, and often, the culprit is price gouging by big pharmaceutical corporations. It has to stop.”
“Our bill would for the first time impose stiff penalties on drug companies that gouge the prices of medicines that their patients rely on for lifesaving treatment,” added Sen. Kirsten Gillibrand (D-New York), one of the bill’s five original cosponsors.
To underscore the reasons for her support, Gillibrand noted the decision by makers of the EpiPen to “cruelly” inflate the price for that emergency allergy treatment, “some even by as high as over 5,000 percent, just because they could get away with it, without any concern for how their actions would affect sick New Yorkers who are desperate for access to life-saving medicine.”
Corporate accountability: Sen. Al Franken (D-Minnesota), another original cosponsor of S. 1369, also cited corporate accountability, saying the pharmaceutical industry needs to put the livelihoods of patients ahead of profits.
“Without explanation, millions of Americans see their drug bills become more and more unaffordable each year,” said Franken. “Our bill would help keep price gouging in check by forcing drug companies to justify price spikes and penalizing them if they can’t.”
In addition to Gillibrand and Franken, the other original cosponsors of the Stop Price Gouging Act are Democratic Sens. Jack Reed of Rhode Island, Maggie Hassan of New Hampshire and Tom Udall of-New Mexico. After the bill’s June 15 introduction, two more Senators — Democrat Richard Durbin of Illinois and Independent Bernie Sanders of Vermont — also signed on to the legislation.
The bill is pending in the Senate Finance Committee.
If eventual Senate debate on health care reform does allow for floor amendments, look for this group of lawmakers to try to have the provisions in their drug price gouging bill added to the measure.
You also might find these items of interest:
- 4 Obamacare taxes the GOP vows to end
- ‘Pharma Bro’ Martin Shkreli facing $4.6 million tax lien
- GOP gets tax reform head start by killing Obamacare taxes in its replacement health care plan